Effective TIL Therapy for Patients with Checkpoint-Resistant Melanoma without Lymphodepleting Regimens Requires IFNα
Taken together, our low-toxicity therapy comprising TIL, nivolumab, and IFNα is safe, shows evidence of clinical activity, and may be particularly suitable for more frail patients who are less able to tolerate lymphodepletion and high-dose IL-2 regimens.
Authors
- Caroline E. van der Minne
- Ellen Kapiteijn (ORCID: https://orcid.org/0000-0002-4814-6426)
- Gerrit‐Jan Liefers (ORCID: https://orcid.org/0000-0001-7326-8313)
- Saskia J. Santegoets (ORCID: https://orcid.org/0000-0002-2874-4402)
- Sjoerd H. van der Burg (ORCID: https://orcid.org/0000-0002-6556-0354)
- Inge C.F.M. Roozen
- Linda de Bruin (ORCID: https://orcid.org/0009-0001-5296-7542)
- Els M.E. Verdegaal (ORCID: https://orcid.org/0000-0002-4449-8707)
- Pauline Meij (ORCID: https://orcid.org/0000-0003-3370-9932)
- Monique K. van der Kooij (ORCID: https://orcid.org/0000-0002-9764-5467)
- Mare A. Jonker
- Frank M. Speetjens (ORCID: https://orcid.org/0000-0003-2065-9593)
- Vera Weeda
- Marten Visser (ORCID: https://orcid.org/0000-0002-8544-131X)
- Inge M. Westra
- Stephanie M. Zunder
- Anique L.C. Verpoorte (ORCID: https://orcid.org/0009-0008-7722-1609)
Institutions
- Leiden University Medical Center (NL)
- Oncode Institute (NL)
Publication Details
- Journal
- Clinical Cancer Research
- Published
- 2025-05-06
- DOI
- https://doi.org/10.1158/1078-0432.ccr-24-4322
- Citations
- 2
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 2.09
Funders
- Leids Universitair Medisch Centrum